Maitreya Medicare Ltd.
MAITREYA.NS
National Stock Exchange of India135.00
INR
+2.00
- -
Maitreya Medicare Ltd.
MAITREYA.NS
(National Stock Exchange of India)
Recent
price
135.00
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Maitreya Medicare Ltd (MAITREYA.NS) operates a 125-bed multispecialty hospital in Surat, Gujarat, providing multidisciplinary integrated healthcare services focused on primary, secondary, and tertiary care. The company offers comprehensive medical services across over 18 specialties and super specialties, including cardiology; urology; laparoscopic surgery; oncology; neurosurgery; spine surgery; neurology; nephrology including dialysis; gastroenterology; gastrointestinal surgery; cardiothoracic surgery; oncosurgery; orthopedic surgery including joint replacements and arthroscopic surgeries; gynecology and high-risk obstetrics; hepatocellular biliary surgery; and critical care medicine. Its facility features a cath lab equipped with IVUS/FFR/Rota and a 20-bed intensive care unit (ICU) with ECMO/CRRT ventilators and monitors, alongside support services such as pathology and radiology. Incorporated in 2019 and headquartered at Someshwar Circle, Udhana-Magdalla Road, Vesu, Surat, Gujarat 395007, India, the company originally commenced as Maitreya Medicare Private Limited before converting to a public limited company and listing on the NSE SME platform in November 2023. It serves patients primarily in the densely populated South Gujarat region, targeting underserved micro-markets with quality secondary and tertiary care under initiatives like Pradhan Mantri Jan Arogya Yojana (PMJAY). Subsidiaries include Maitreya Hospital Private Limited and Maitreya Lifescience Private Limited. In recent developments, the company allocated IPO proceeds announced in late 2023 toward constructing a new 125-bed multispecialty hospital with advanced tertiary care in Valsad, Gujarat, to expand its footprint in South Gujarat; this project aims to introduce full-time super-specialists in cardiology, neurology, and nephro-urology while enhancing capacity potentially to 200 beds with services like organ transplants and robotics. No major acquisitions, partnerships, funding rounds, or name changes have been reported in the last 1-2 years beyond standard regulatory filings such as related-party disclosures and shareholding patterns in 2025.